Due to the significant clinical impact, guidelines for the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) recommend testing for del(17p) via fluorescence in situ hybridization (FISH) and TP53 mutation status via DNA sequencing prior to initiating treatment. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.